Session » Sjögrenʼs Syndrome – Basic & Clinical Science Poster I
-
Abstract Number: 2413
LOU064: A Highly Selective and Potent Covalent Oral BTK Inhibitor with Promising Pharmacodynamic Efficacy on B Cells for Sjoegren’s Syndrome
-
Abstract Number: 2414
Efficacy and Safety of Abatacept in Patients with Early Active Primary Sjögren’s Syndrome – Open-label Extension Phase of a Randomized Controlled Phase III Trial
-
Abstract Number: 2415
Evaluation of Pharmacokinetics and Immunogenicity Following Subcutaneous Administration of Abatacept in Primary Sjogren ’s Syndrome (pSS) and RA Patients
-
Abstract Number: 2416
ALPN-101, a First-in-Class Dual ICOS/CD28 Antagonist, Suppresses Key Effector Mechanisms Associated with Sjögren’s Syndrome
-
Abstract Number: 2417
A Phase 2a Study of MEDI5872 (AMG557), a Fully Human Anti-ICOS Ligand Monoclonal Antibody in Patients with Primary Sjögren’s Syndrome
-
Abstract Number: 2418
Tofacitinib Inhibits Increased Inflammatory Marker Expression in a Human Salivary Cell Line Deficient in Autophagy: A Model of Sjögren’s Syndrome
-
Abstract Number: 2419
An ex-vivo Assay to Evaluate the Efficacy of Different Treatments for Inhibiting B Lymphocytes Activation by Salivary Gland Epithelial Cells in Sjögren’s Syndrome
-
Abstract Number: 2420
Role of T Follicular Helper Cells and T Peripheral Helper Cells in the Activation of B Cells in Sjögren Syndrome
-
Abstract Number: 2421
Circulating CCR7loPD-1hi Follicular Helper T Cells Indicate Disease Activity and Glandular Inflammation in Patients with Primary Sjögren’s Syndrome
-
Abstract Number: 2422
Increased Apoptosis and Compromised Suppressive Capacity of Regulatory T Cells in Primary Sjögren’s Syndrome
-
Abstract Number: 2423
In Primary Sjogren’s Syndrome (pSS) IL7 Promotes the Crosstalk Between T Lymphocytes and Salivary Gland Epithelial Cells and Participates to IFN Signature
-
Abstract Number: 2424
RORγt Antagonist Attenuates Experimental Sialadenitis Like Sjögren’s Syndrome via Inhibition of CD25 Expression on CD4+ T Cells
-
Abstract Number: 2425
The anti-Ro52 Prevalence in the Sjögren’s Syndrome Picture: A Single Center Cross Sectional Study
-
Abstract Number: 2426
Distinct Clinical Characteristics of Anti-Ro/SSA Negative Primary Sjögren’s Syndrome: Data from a Cohort for Sjögren’s Syndrome in Korea
-
Abstract Number: 2427
The Positivity for Anti-centromere Antibody Makes Distinct Clinical Features in Primary Sjogren’s Syndrome : Data from a Prospective Korean Nation-wide Cohort
-
Abstract Number: 2428
Serum Myositis Specific/associate Autoantibodies Help Identify Early Connective Tissue Diseases Relevant Interstitial Lung Diseases: A Medical Center Experience
-
Abstract Number: 2429
Zipcode-Binding Protein 1 (ZBP1) Facilitates Ro60 Surface Translocation, Cellular Growth and Autoimmune Sequelae
-
Abstract Number: 2430
Detection and Clinical Significance of Circulating M3 Muscarinic Acetylcholine Receptor Reactive Th17 Cells in Patients with Primary Sjögren’s Syndrome
-
Abstract Number: 2431
Extracellular Vesicles in Primary Sjögren’s Syndrome: A Promising Source for Novel Proteomic Biomarkers
-
Abstract Number: 2432
Thymic Stromal Lymphopoietin (TSLP) as a Biomarker of Primary Sjögren’s Syndrome (pSS) and Related Lymphoma: Results in Independent Cohorts
-
Abstract Number: 2433
Fatigue in Primary Sjögren’s Syndrome as a Manifestation of Heavier Disease Activity of Mucosa-Associated Lymphoid Tissue (MALT)
-
Abstract Number: 2434
Risk of Lymphoma and Thyroid Cancer in Primary Sjögren’s Syndrome Measured Using the Korean Health Insurance Claims Database
-
Abstract Number: 2435
Data Driven Prediction Lymphoma Model and 10-year Overall Survival Rates of a Large Harmonized Cohort of Patients with Primary Sjögren’s Syndrome Associated Lymphomas